Diurnal has created a pipeline of enhanced product opportunities within the endocrine area, where current therapies are considered to be sub-optimal and could be superseded with more effective physiological hormonal replacement products.

  • Chronocort®: our goal is to develop a first-in-class hydrocortisone product for the lifelong treatment of congenital adrenal hyperplasia and adrenal insufficiency
  • Infacort®: our intention is to create a first-in-class paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency
  • Native Oral Testosterone: our objective is to create a native oral testosterone treatment for hypogonadism
  • Tri4Combi™: our target is to develop the first combination therapy product of thyroid hormones for patients suffering from hypothyroidism